Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Imugene ( (AU:IMU) ) has provided an announcement.
Imugene Limited has applied for quotation on the ASX of 929,427 new ordinary fully paid shares, issued on 6 January 2026 following the exercise or conversion of existing options or other convertible securities. The modest increase in quoted securities reflects ongoing capital management and shareholder participation in equity-linked instruments, incrementally broadening the company’s free float and potentially enhancing liquidity in its stock without materially altering its overall capital structure.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.36 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is an Australian biotechnology company listed on the ASX under the code IMU. It operates in the life sciences sector, focusing on developing innovative immunotherapies and related biopharmaceutical technologies for medical markets.
Average Trading Volume: 1,558,787
Technical Sentiment Signal: Sell
Current Market Cap: A$114.2M
For an in-depth examination of IMU stock, go to TipRanks’ Overview page.